Ra Medical Systems, Inc. (NYSE:RMED) is set to announce third quarter earning results on Thursday 12th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, RMED to report 3Q20 loss of $ 0.13 per share.
For the full year, analysts anticipate top line of $ 4.76 million, while looking forward to loss of $ 1 per share bottom line.
Previous Quarter Performance
Ra Medical Systems, Inc. disclosed loss for the second quarter of $ 0.43 per share, from the revenue of $ 0.90 million. The quarterly revenues fell 58.14 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.22 per share from $ 0.55 million in revenue. The bottom line results missed street analysts by $ 0.21 or 95.45 percent, at the same time, top line results outshined analysts by $ 0.35 million or 63.64 percent.
Stock Performance
Shares of Ra Medical Systems, Inc. traded low $ 0.00 or -1.57 percent on Wednesday, reaching $ 0.21 with volume of 857.60 thousand shares. Ra Medical Systems, Inc. has traded high as $ 0.21 and has cracked $ 0.20 on the downward trend
The closing price of $ 0.21, representing a 23.53 % increase from the 52 week low of $ 0.17 and a 92.19 % decrease over the 52 week high of $ 2.69.
The company has a market capital of $ 14.97 million and is part of the Healthcare sector and Medical Devices industry.
Conference Call
Ra Medical Systems, Inc. will be hosting a conference call at 4:30 PM eastern time on 12th November 2020, to discuss its 3Q20 financial results with the investment community. The participants may dial, 866-777-2509 Toll Free, (United States) or 412-317-5413 Toll Number, when prompted, enter passcode 10149446 in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website www.ramed.com
Ra Medical Systems, Inc., a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological diseases. The company offers DABRA (destruction of arteriosclerotic blockages by laser radiation ablation), a minimally-invasive excimer laser and disposable catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. It also provides Pharos, an excimer laser device that emits highly concentrated ultraviolet light used in the treatment of dermatological skin disorders.
